CME Presentations
Prostate Cancer
Presentations
Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients
Speakers: Neal D. Shore, MD, FACSSimpa Salami, MD, MPH, Urologic Oncologist and Assistant Professor of Urology Duration: 30 minutes
Presented on: December 14, 2020
Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
Speakers: A. Oliver Sartor, MD, Professor of MedicineNeal D. Shore, MD, FACSTomasz (Tom) Beer, MD, FACP, Professor of Medicine, Hematology & Medical Oncology Duration: 60 minutes
Presented on: December 14, 2020
Optimizing Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Speakers: A. Oliver Sartor, MD, Professor of MedicineNeal D. Shore, MD, FACSTomasz (Tom) Beer, MD, FACP, Professor of Medicine, Hematology & Medical Oncology Duration: 60 minutes
Presented on: December 14, 2020
PARP Inhibition: A New Paradigm in Prostate Cancer Care
Speakers: Neal D. Shore, MD, FACSDavid Quinn, MD, Associate Professor of Medicine (Clinical Scholar) Duration: 30 minutes
Presented on: December 14, 2020
Speakers
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS
Neal D. Shore, MD, FACS is the Medical Director for the Carolina Urologic Research Center. He practices with Atlantic Urology Clinics in Myrtle Beach, South Carolina.
Dr. Shore has conducted more than 350 clinical trials, focusing mainly on GU Oncology, and serves on the Executive Boards of: Society of Urologic Oncology Board, Bladder Cancer Advocacy Network, and is Immediate Past President, Large Urology Group Practice Association. He is a founder for both: CUSP Clinical Trials Consortium, as well as for DASHKO, large urology practices data registries. He serves as the National Urology Research Director for 21st Century Oncology. He has served on the AUA Male Health Committee and the AUA Data Committee, the SITC Task Force for Prostate Cancer, the Bladder Cancer Advocacy Think Tank and the editorial boards of Reviews in Urology, Urology Times, Chemotherapy Advisor, OncLive, PLOS ONE(Academic Editor), Urology Practice, World Journal of Urology, and serves as Editor, Everyday Urology-Oncology. He has more than 175 peer reviewed publications and numerous book chapters; he performs peer review for Lancet Oncology, New England Journal of Medicine, European Urology, Journal Urology, Urology, BJUI, PCPD, and numerous other high impact scientific journals.
A graduate of Duke University and Duke University Medical School, Dr. Shore completed a 6-month clinical research fellowship in Pretoria, South Africa, and then completed his General Surgery/Urology training at New York Hospital Cornell Medical Center and at Memorial Sloan-Kettering Cancer Center in New York City. He is a Fellow of the American College of Surgeons.
Simpa Salami, MD, MPH
Simpa Salami, MD, MPH
Urologic Oncologist and Assistant Professor of Urology
A. Oliver Sartor, MD
A. Oliver Sartor, MD
Professor of Medicine
Oliver Sartor, MD, is the C.E. and Bernadine Laborde professor of cancer research, medical director of the Tulane Cancer Center, and assistant dean for oncology at Tulane University School of Medicine in New Orleans, Louisiana. His clinical and research interests have focused broadly on prostate cancer over the years. Dr Sartor’s more than 400 scientific publications range from genetic studies on prostate cancer to studies of ethnic populations. He has given hundreds of lectures and presentations on advanced prostate cancer at meetings in 33 countries. Dr Sartor was past chief editor of Clinical Genitourinary Cancer and a reviewer for numerous peer-reviewed publications. He is medical oncology chair of the Genitourinary Cancer Committee of the NRG, a national clinical trials cooperative.
Tomasz (Tom) Beer, MD, FACP
Tomasz (Tom) Beer, MD, FACP
Professor of Medicine, Hematology & Medical Oncology
David Quinn, MD
David Quinn, MD
Associate Professor of Medicine (Clinical Scholar)
CME Information
2nd Annual Virtual Summit: Optimizing Uro-Oncology Care for Patients with Metastatic and Nonmetastatic Prostate Cancer
EDUCATIONAL OBJECTIVES
After completing this activity, the participant should be better able to:
Session One: Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients- Review the rationale behind biomarker testing in prostate cancer to assess patients’ risk and prognosis and determine treatment
- Discuss how molecular testing in patients with prostate cancer can guide treatment selection
- Review the recent recommendations by NCCN, AUA, and ASCO regarding molecular testing in patients with prostate cancer
- Implement physician-patient communication strategies to inform and counsel patients and prostate cancer about molecular testing
- Evaluate when to initiate antiandrogen therapy in asymptomatic nmCRPC patients with a rising PSA
- Assess the new and emerging clinical evidence from practice-changing clinical trials for treatment strategies in nmCRPC
- Review the approaches to mitigating side effects associated with antiandrogen therapy for patients with nmCRPC
- Evaluate existing and emerging therapeutic options for patients with mCRPC
- Select optimal therapies for patients with mCRPC with and without visceral metastases
- Review novel emerging treatment strategies that are currently being investigated in phase III clinical trials of prostate cancer
- Review the role of PARP inhibitors in prostate cancer treatment and hot to mitigate adverse events associated with this therapy
- Address misconceptions of patients who may not recognize the utility of PARP inhibitors in the treatment of prostate cancer
These activities are jointly provided by Global Education Group and PlatformQ Health Education, LLC, in collaboration with Large Urology Group Practice Association (LUGPA).ACKNOWLEDGEMENT
This activity is supported by educational grants from Advanced Accelerator Applications USA, Inc., Astellas Pharma Inc., Clovis Oncology, Dendreon, Myriad, and Sanofi.TARGET AUDIENCE
The educational design of these activities addresses the needs of medical oncologists, radiation oncologists, urologists, nuclear medicine, nurses, pharmacists, and advanced practice providers.STATEMENT OF NEED/PROGRAM OVERVIEW
In the United States, prostate cancer is the second leading cause of death after skin cancer in men. Urologists and oncologists who care for patients with prostate cancer need to remain updated regarding advancements in prostate cancer management. In addition to new evidence-based treatment strategies for metastatic and nonmetastatic disease, novel targeted therapies, and predictive and prognostic biomarkers are allowing clinicians to treat patients who could not be treated before. Collectively these advances improve patient outcomes yet create knowledge and practice gaps for clinicians. Urologists, oncologists, and other health care professionals need education on the use of biomarker testing to assess patients’ disease risk, new and emerging treatment options, identifying and managing treatment-related adverse events, and strategies for selecting the most appropriate treatment for individual patients.SESSION ONE: Utilizing Biomarkers to Navigate Treatment Decisions for Prostate Cancer Patients
Activity Overview
TbaDATE OF RELEASE/EXPIRATION
December 14, 2020 – December 14, 2021PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.SESSION TWO: Integrating New Therapies in the Management of Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)
Activity Overview
TbaDATE OF RELEASE
Monday, December 14, 2020 11:00 am – 12:00 pm EST.DATE OF RELEASE/EXPIRATION
December 14, 2020 – December 14, 2021PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.SESSION THREE: Optimizing Treatment for Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC)
Activity Overview
TbaDATE OF RELEASE
Monday, December 14, 2020 12:00 – 1:00 pm EST.DATE OF RELEASE/EXPIRATION
December 14, 2020 – December 14, 2021PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 1 hour to complete.SESSION FOUR: PARP Inhibition: A New Paradigm in Prostate Cancer Care
Activity Overview
TbaDATE OF RELEASE/EXPIRATION
December 14, 2020 – December 14, 2021PHYSICIAN ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and PlatformQ Health Education, LLC. Global is accredited by the ACCME to provide continuing medical education for physicians.PHYSICIAN CREDIT DESIGNATION
Global Education Group designates this enduring activity for a maximum of 0.50 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.ESTIMATED TIME TO COMPLETE
This activity should take approximately 30 minutes to complete.INSTRUCTIONS TO RECEIVE CREDIT
In order to receive credit for each activity, the participant must (1) read the target audience, learning objectives, and disclosure statements, (2) complete the educational activity online, and (3) complete the post-test and activity evaluation. To receive AMA PRA Category 1 Credits™, participants must receive a minimum score of 70% on the post-test.HARDWARE/SOFTWARE REQUIREMENTS
Participants will need a computer with a recent version of Adobe Flash installed, as well as an internet connection sufficient for streaming media.FEE INFORMATION & REFUND/CANCELLATION POLICY
There is no fee for any of these educational activities.DISCLOSURE OF CONFLICTS OF INTEREST
Global Education Group (Global) requires instructors, planners, managers, and other individuals and their spouses/life partners who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations. The faculty reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:Name of Faculty or Presenter Reported Financial Relationship Neal D. Shore, MD, FACS
Medical Director, CPI
Carolina Urologic Research Center
Atlantic Urology ClinicsTBA Oliver Sartor, MD
C.E. and Bernadine Laborde Professor of Cancer Research,
Assistant Dean for Oncology,
Tulane University School of Medicine;
Medical Director,
Tulane Cancer CenterConsultant/Independent Contractor: Advanced Accelerator Applications (AAA), Astellas, AstraZeneca, Bayer, Blue Earth Diagnostics, Inc., Bavarian Nordic, Bristol Myers Squibb, Clarity Pharmaceuticals, Clovis, Constellation, Dendreon, EMD Serono, Fusion, Isotopen Technologien Meunchen, Janssen, Myovant, Myriad, Noria Therapeutics, Inc., Novartis, Noxopharm, Progenics, POINT Biopharma, Pfizer, Sanofi, Tenebio, Telix, Theragnostics Grant/Research Support: Advanced Accelerator Applications, AstraZeneca, Bayer, Constellation, Dendreon, Endocyte, Invitae, Janssen, Merck, Progenics, Sanofi, SOTIO Tomasz M. Beer, MD, FACP
Grover C. Bagby Endowed Chair for Prostate Cancer Research
Deputy Director, OHSU Knight Cancer Institute
Chief Medical Officer, CEDAR
Professor of Medicine, Hematology & Medical Oncology
Director, Prostate Cancer Research Program
Oregon Health & Science University
Portland, OregonTBA Simpa S. Salami MD, MPH
Assistant Professor of Urology
Division of Urologic Oncology
Department of Urology
University of Michigan
Ann Arbor, MichiganNothing to disclose David I. Quinn MD
Associate Professor of Medicine (Clinical Scholar)
Section Head, Genitourinary (GU) Oncology, Division of Cancer Medicine and Blood Diseases in the Department of Medicine
Health Sciences Campus
Los Angeles, CATBA
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Name of Faculty or Presenter Reported Financial Relationship Lindsay Borvansky Nothing to disclose Andrea Funk Nothing to disclose Liddy Knight Nothing to disclose Ashley Cann Nothing to disclose Tariqa Ackbarali Nothing to disclose Bridget Griffin Nothing to disclose
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and PlatformQ Health Education, LLC. do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.DISCLAIMER:
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.CONTACT INFORMATION
Accreditation Support:
For information about the accreditation of this program, please contact Global at 303-395-1782 or cme@globaleducationgroup.com.
Technical Support:
For any technical issues or issues with your CME Certificate, please contact UroCareLive or OMedLive at 877-394-1306 or at support@omedlive.com
